Investors
Quarterly Reports
Q3 2018 Report
Tuesday, 6 NovemberMeeting room HolmenkollenThe webcast will be streamed LIVE and the recording will be available after LIVE session is finished.
Link to live webcastScientific Presentations
60th American Society of Hematology Meeting (ASH)
Dec 1 - 4 2018San Diego
Poster presentation by Loges et al:
Comprehensive Analysis of the Dose Escalation, Expansion and Correlates in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS
Read More
Annual Report 2017
BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.
Our annual report
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159 (general) + 47 535 01 564 (urgent medical enquiries)